Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 ...
The reduced monthly HAE attack rate was maintained for at least 1.5 years in the CHAPTER-1 OLE study. What improvements did participants report in the CHAPTER-1 OLE study? All participants ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...
Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...
“The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack ...
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results